FOXO1-IN-3 (Compound 10) (10 μM, 6 h) suppresses cAMP/Dexamethasone induced G6pc and Pck1 mRNA expression in primary hepatocytes isolated from normal mice[1].
FOXO1-IN-3 (Compound 10) (16 mg/kg, p.o., twice daily, for 10 days) reduces blood glucose in db/db mice[1].
FOXO1-IN-3 (16 mg/kg, p.o., twice daily, for 7 days) and FGF21 (0.45 mg/kg) has synergistic glucose-lowering effects in Streptozotocin induced β-cell-ablated diabetic mice[1].
FOXO1-IN-3 (1 mg/kg for i.v., 10 mg/kg for p.o.) shows significant plasma exposure and oral bioavailability despite relatively short half-life in mice[1].
PK properties of FOXO1-IN-3 (compound 10)
References:
[1]. Lee YK, et al. FOXO1 inhibition synergizes with FGF21 to normalize glucose control in diabetic mice. Mol Metab. 2021 Jul;49:101187.